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j Abstract The article reviews the current knowl-
edge about the impulse control disorders (ICDs) with
speciﬁc emphasis on epidemiological and pharmaco-
logical advances. In addition to the traditional ICDs
present in the DSM-IV—pathological gambling,
trichotillomania, kleptomania, pyromania and inter-
mittent explosive disorder—a brief description of the
new proposed ICDs—compulsive–impulsive (C–I)
Internet usage disorder, C–I sexual behaviors, C–I
skin picking and C–I shopping—is provided. Specif-
ically, the article summarizes the phenomenology,
epidemiology and comorbidity of the ICDs. Particular
attention is paid to the relationship between ICDs and
obsessive–compulsive disorder (OCD). Finally, cur-
rent pharmacological options for treating ICDs are
presented and discussed.
j Key words impulse control disorders (ICDs) Æ
obsessive–compulsive disorder (OCD) Æ pathological
gambling (PG) Æ kleptomania Æ compulsive–impulsive
(C–I) shopping Æ trichotillomania (TTM) Æ intermit-
tent explosive disorder (IED) Æ C–I Internet usage
disorder Æ C–I sexual behaviors (C–ISBs) Æ C–I skin
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Introduction
Since the early 1990s, some researchers have sug-
gested that the impulse control disorders (ICDs)
might be conceptualized as a part of an obsessive–
compulsive spectrum based on their clinical charac-
teristics, familial transmission, and response to both
pharmacological and psychosocial treatment inter-
ventions [1–3]. Over a decade of study and scientiﬁc
developments have led a DSM-V task force to con-
sider two important changes: separating obsessive–
compulsive disorder (OCD) from the anxiety disor-
ders and placing it in an autonomous category—the
obsessive–compulsive spectrum disorders (OCSD);
and creating several new autonomous disorders from
those currently subsumed under ICDs not otherwise
speciﬁed (ICD-NOS) [4], speciﬁcally including four
new impulsive disorders, compulsive–impulsive (C–I)
Internet usage disorder C–I sexual behaviors, C–I skin
picking and C–I shopping. They are called compul-
sive–impulsive disorders due to the impulsive fea-
tures (arousal) that initiate the behavior, and the
compulsive drive that causes the behaviors to persist
over time.
The relationship between OCD and the OC spec-
trum has been supported by studies over the past
decade, although recent studies have also supported
additional models. Recent neuroimaging (PET, fMRI
etc.) and genetics studies have increased under-
standing of the biological and neuroanatomical
characteristics of the ICDs and have supported both
the OC spectrum model and suggested other models
[5, 6]. The pharmacological options, moreover, have
been expanded based on recent research; traditional
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(SRIs) supported the OC spectrum model, but recent
research demonstrating the efﬁcacy of different
pharmacological interventions suggests that addi-
tional systems are involved and other models may be
useful. For example, the efﬁcacy of pharmacothera-
pies acting on different systems of neuromediators
(opioid antagonists, mood stabilizers, dopamine re-
uptake inhibitors), support different theoretical
models for the ICDs and make clear that it is valuable
to look at the ICDs from different theoretical per-
spectives that suggest different mechanisms might be
important and raise new research questions.
ICDs’ phenomenology, epidemiology and
relationship with OCD
ICDs are characterized by repetitive behaviors and
impaired inhibition of these behaviors. Important
deﬁning criteria for these disorders include:
1. The failure to resist an impulse to perform some act
that is harmful to the individual or others;
2. An increasing sense of arousal or tension prior to
committing or engaging in the act;
3. An experience of either pleasure, gratiﬁcation, or
release of tension at the time of committing the act.
In addition, there is usually a pattern of engaging
in the abnormal behavior in spite of adverse conse-
quences (e.g., criminal changes, impairment of nor-
mal functioning, etc.). To demonstrate that a
relationship exists between ICDs and OCD, there
should be evidence that OCD is overrepresented in
patients with ICDs and/or that ICDs are overrepre-
sented in patients with OCD. Studies examining rates
of OCD in patients with ICDs have reported incon-
sistent results, with some ICDs showing relatively
high rates of comorbidity with OCD (trichotillomania,
CI-shopping), and others demonstrating low rates
(intermittent explosive disorder, pathological gam-
bling, and C–I sexual behaviors).
Pathological gambling (PG) is an impulse control
disorder not otherwise speciﬁed (ICD-NOS) [4] that is
characterized by recurrent and maladaptive patterns
of gambling behavior that signiﬁcantly disrupts the
patient’s functioning in the personal, familial, or
vocational spheres. Recent studies suggest that the
prevalence of PG is between 1% and 3% of the adult
population [7, 8], and a meta-analysis [9] estimated
that 86% of the population of the USA are recreational
gamblers (Table 1). The disorder usually starts during
adolescence with a prevalence of approximately 4–7%
in this population. However, over the last decade,
there has been an unprecedented expansion of legal-
ized gambling throughout North America, and, as a
result, the prevalence of PG can be expected to in-
crease. The disorder is currently more common in
men than in women. Recent national studies on PG
prevalence have also been conducted in New Zealand
[10–12], Sweden [13, 14], Switzerland [15], Australia
[16] and Great Britain [17], and despite the use of
different methodologies and variable technical qual-
ity, problem gambling prevalence studies have shown
a high degree of consistency in their general ﬁndings.
A crucial issue to consider is the high rate of
comorbidity among pathological gamblers. Patients
with PG, at least those seeking treatment, have been
found to score signiﬁcantly higher than control pop-
ulations on measures of depression [18], and have
high incidences of various psychiatric disorders,
including bipolar, anxiety and substance use disor-
ders [19]. This frequent comorbidity is not surprising
given the psychopathological core features of PG:
impulsivity, compulsive drive to gamble, addictive
features such as withdrawal symptoms during gam-
bling abstinence, and bipolar features such as urges,
pleasure seeking and decreased judgment due to
unrealistic appraisal of the individuals’ own abilities.
Several authors have noted the link between various
core features of PG and neurobiological characteris-
Table 1 Prevalence estimates of impulse control disorders
Impulse control disorder Reference Type of community Prevalence reported
Pathological Gambling Gerstein et al. (1999) Adult population 1–3%
Welte et al. (2001) Adult population
Trichotillomania Christenson et al. (1991) College students 1.5% males; 3.4 females
Pyromania Kosky and Silburn (1984) Children and adolescents 2.4–3.5%
Kolko et al. (1988) Children and adolescents
Jacobson (1995) Children and adolescents
Intermittent Explosive Disorder Monopolis and Lion (1983) Psychiatric surveys 1–2%
Coccaro et al. (2004) Adult population Lifetime 11.1%; 1 month 3.2%
Kleptomania Goldman (1991) Adult population 0.6%
C–I Internet Usage Disorder –– –
C–I Shopping Black et al. (2001) Adult population 2–8%
C–I Skin Picking Doran et al. (1985) Dermatologic patients 2%
Gupta et al. (1986) Dermatologic patients
C–I Sexual Behaviors Shaffer and Zimmerman (1990) Adult population 5–6%
Coleman, 1991 Adult population
465tics or treatment-response, and have conceptualized
PG according to different models, thus placing it on
different spectrums with the main psychiatric disor-
ders of reference being OCD [1], addictive disorders
[20], and affective disorders [21]. These models pro-
vide the theoretical rationale for the use of speciﬁc
pharmacological treatments in PG. In addition, the
models and related research ﬁndings may also suggest
the presence of speciﬁc subgroups of patients with
similar core features, comorbidity proﬁles and treat-
ment-response within the population of pathological
gamblers [22, 23]. The relationship between PG and
OCD has allowed PG to be conceptualized as an OC
spectrum disorder, within the impulsive cluster [1].
Patients with OC spectrum disorders, in fact, experi-
ence unpleasant feelings and physiological activation
that result in an intense desire to perform a speciﬁc
behavior in order to relieve the unpleasant feelings
[24, 25]; this is the case in PG. In addition, a reduced
capacity to resist gambling thoughts and urges leads
to excessive gambling, in particular in the advanced
phases of the disorder [26]. However, these patients
differ from patients with OCD in important ways.
Gambling behavior and thoughts are often experi-
enced by these patients as ego-syntonic, while OCD
obsessions and compulsions are generally ego-dys-
tonic. In addition, the excessive doubt frequently
experienced by OCD patients [24, 27, 28], as well as
their harm avoidance, risk aversion and anticipatory
anxiety [29], are not characteristic of pathological
gamblers. OC spectrum disorders differ along the
dimension of risk aversion vs. risk taking; the com-
pulsive disorders are characterized by an overesti-
mation of harm and by risk aversion while the
impulsive disorders are characterized by an under-
estimation of risk and by risk seeking. Recently, the
rate of comorbid OCD in individuals with PG was
found to range from 1% to 20% [30] (Table 2).
Patients afﬂicted with trichotillomania (TTM) de-
scribe an overwhelming urge to pluck out speciﬁc
hairs; when they do so, the anxiety is momentarily
relieved but is quickly replaced by another compul-
sive urge to pluck and even greater anxiety [31]. The
exact prevalence of TTM is unknown; however, esti-
mates from university surveys suggest that 1.5% of
males and 3.4% of females endorse clinically signiﬁ-
cant hair pulling, with .6% endorsing all diagnostic
criteria of TTM [32] (Table 1). The prevalence of non-
clinical hair pulling behavior is even higher, up to
15.3%, in university surveys [33] (Table 1). In
describing the phenomenological similarities between
OCD and TTM, Swedo [34] highlighted the egodys-
tonic feeling and the resistance experienced by pa-
tients with TTM and OCD. In addition, patients with
TTM recognize the behavior as senseless, undesirable
and performed in response to increasing anxiety, with
resultant tension relief. Furthermore, a higher than
normal incidence of both OCD and TTM has been
reported in ﬁrst-degree relatives of patients with TTM
[35], and comorbidity data also support a relationship
between OCD and TTM [36, 37] (Table 2). However,
recent investigations [38, 39] have also included TTM
in a spectrum of self-injurious behaviors (SIBs),
including C–I skin picking, and underscored the
phenomenological link among these SIBs and the
differences between TTM and OCD [39].
In pyromania there is impulsive, repetitive, delib-
erate ﬁre setting without external reward (e.g., arson
for money, revenge, as a political act). There are very
few community sample studies of ﬁresetting, which is
understandable since it is illegal and thus likely to be
kept secret. The majority of epidemiological studies
have focused on pyromania in childhood and ado-
lescence and have reported the prevalence to be be-
tween 2.4% [40] and 3.5% [41, 42] (Table 1). In
addition, several lines of evidence indicate that ado-
lescent boys may be at higher risk for ﬁresetting than
adolescent girls [43, 44]. Among juveniles, ﬁresetting
is more prevalent in males than females, peaking
between 12 years and 14 years [45]. Sixty percent of
all ﬁres in large U.S. cities are lit by individuals be-
tween 11 years and 18 years [46]. Besides young age,
features such as temperament, parental psychopa-
thology, social and environmental factors, and pos-
sible neurochemical predispositions [47] have been
hypothesized to cause childhood pyromania. Some
Table 2 OCD rates in impulse
control disorders Impulse control disorder Reference Rates of OCD
Pathological Gambling Argo and Black (2004) 1–20%
Trichotillomania Christenson and Mansueto (1999) 3–27%
Pyromania ––
Intermittent Explosive Disorder McElroy et al. (1998) 22%
Kleptomania Presta et al. (2002) 6.5–60%
C–I Internet Usage Disorder Black et al. (1999) 0% current; 10% lifetime
Shapira et al. (2000) 15% current; 20% lifetime
C–I Shopping Christenson et al. (1994) 12.5–30%
McElroy et al. (1998)
C–I Skin Picking Simeon et al. (1997) 6–52%
Arnold et al. (1998)
Wilhelm et al. (1999)
C–I Sexual Behaviors Kafka and Prentky (1994) 12–14%
Black et al. (1997)
466authors have noted a close link between ﬁresetting
and aggression [48] and between ﬁresetting and
antisocial behavior [49]. In addition, published data
have shown high rates of conduct disorder among
young arsonists [50]. Recent ﬁndings, moreover, re-
vealed associations between ﬁresetting and shyness,
aggression and peer rejection [51]. No published
studies of the relationship between pyromania and
OCD in terms of comorbidity or family history are
available.
Intermittent explosive disorder (IED) is charac-
terized by recurrent episodes of aggressive behavior
that is out of proportion to psychosocial stressors
and/or provocation and that is not better accounted
by another mental disorder, comorbid medical con-
ditions, or the physiologic effects of a pharmacologic
agent or other substance with psychotropic properties
[4]. Despite its inclusion in DSM for more than two
decades, there are few studies of the lifetime preva-
lence of IED in either psychiatric or community set-
tings. Clinical surveys of psychiatric inpatients [52],
and clinical treatment studies on IED [53] had found
rates of IED in psychiatric settings ranging from 1%
to 2%. Recently, however, Coccaro and colleagues
reported much higher rates of IED, 11.1% lifetime
prevalence and 3.2% 1-month prevalence, in a com-
munity sample of 253 individuals [54] (Table 1).
Based on these data, the authors estimated there are
1.4 million individuals with current IED in the US and
10 million with lifetime IED. As the authors suggested,
prevalence rates so much higher than prior ﬁndings
may reﬂect the changes in diagnostic criteria of IED
from DSM-III [55] to DSM-IV [4] as well as the
changes recently proposed in the development of re-
search criteria for IED [56, 57]. A study by McElroy
and colleagues reported rates of OCD in individuals
with IED around 22% [58] (Table 2); recent studies
investigating the rates of IED in patients with OCD
have given lower estimates [59–61].
Kleptomania is a disorder in which the individual
impulsively steals even though there is need to do so
(i.e., the individual has money to pay for the stolen
items or does not need the stolen goods). Like other
ICDs, kleptomania is characterized by an anxiety-
driven urge to perform an act that is pleasurable in
the moment but causes signiﬁcant distress and dys-
function [62]. The prevalence of kleptomania in the
U.S. is unknown but has been estimated at 6 per 1000
people. [63] (Table 1). In addition, given the embar-
rassment surrounding kleptomania, it is often kept
secret and thus goes undiagnosed [62]. Kleptomania
is thought to account for 5% of shoplifting in the U.S.
[64]. Based on total shoplifting costs of $10 billion in
2002 [65], this 5% translates into a $500 million an-
nual loss to the economy attributable to kleptomania.
This loss does not include the costs associated with
stealing from friends and acquaintances or costs in-
curred by the legal system. Kleptomanic behavior
carries serious legal consequences: approximately 2
million Americans are charged with shoplifting
annually [66]. If kleptomania accounts for 5% of
these, this translates into 100,000 arrests. Recent
studies assessing the rate of OCD in patients with
kleptomania have given widely differing estimates,
ranging from 6.5% to 60% [67, 68] (Table 2).
C–I Internet usage disorder, also referred as In-
ternet addiction or problematic Internet use, has been
proposed as an explanation for uncontrollable and
damaging use of the Internet, and has only recently
begun to appear in the psychiatric literature [69, 70].
People with problematic Internet use often report
increasing amounts of time-spent web surﬁng, gam-
bling, shopping or exploring pornographic sites.
Others report spending time in chat rooms or corre-
sponding by email. Frequently these people develop a
preoccupation with the Internet, a need for escape to
the Internet and increasing irritability when trying to
cut back their Internet use. Ultimately, their attempt
to cut back is unsuccessful. Functional impairments
as a result of problematic Internet use include marital
or family strife, job loss or decreased job productivity,
legal difﬁculties or school failure [72]. Although
diagnostic criteria for this disorder have been pro-
posed, methods of assessing C–I Internet usage dis-
order are limited. In addition, although increasing
research is being conducted on the topic, several
published articles contain information that has not
been empirically researched [73]. For some individ-
uals, their excessive Internet use may be entirely ac-
counted for by another Axis I disorder such as PG or
C–I sexual behaviors; thus the Internet is functioning
simply as another outlet for that disorder rather than
being an additional disorder. Problematic Internet use
has been reported in any age, social, educational, and
economic range [74]. However, while previous studies
tended to stereotype the classical Internet addicted
patient as a young introverted man [75, 76], recent
investigations have showed increasing rates of this
disorder among women [74], as a result of the in-
creased availability of the Internet. The prevalence of
C–I Internet usage disorder is not known. Most of the
studies related to this condition have been conducted
with small samples. People enrolled, moreover, fre-
quently had comorbid psychiatric diagnoses. In a
recent study [71], Shapira and colleagues found that
all subjects with problematic Internet use also met
DSM-IV criteria for ICD-NOS. Studies assessing
comorbidity rates between OCD and C–I Internet use
reported estimates ranging from 10% to 20% for
lifetime OCD and up to 15% for current OCD in In-
ternet addicted patients [71, 77, 78] (Table 2). Further
investigations on the epidemiology of this disorder
are needed to clarify the scale and demographic
characteristics of C–I Internet use.
C–I sexual behaviors (C–ISBs) include repetitive
sexual acts and compulsive sexual thoughts. The
individual feels compelled or driven to perform the
behavior, which may or may not cause subjective
467distress. Although generally not ego-dystonic, the
behavior may interfere with several aspects of the
patient’s life, causing social or occupational impair-
ment, or legal and ﬁnancial consequences [79].
C–ISBs involve a broad range of paraphilic or non-
paraphilic symptoms [80]. Paraphilic C–ISBs involve
unconventional sexual behaviors in which there is a
disturbance in the object of sexual gratiﬁcation or in
the expression of sexual gratiﬁcation (e.g., exhibi-
tionism, voyeurism). Non-paraphilic C–ISBs, on the
other hand, involve conventional sexual behaviors
that have become excessive or uncontrolled [80]. The
true prevalence of C–ISBs remains unknown, given
the hetereogeneity of these disorders as well as the
secretiveness of the condition for the majority of
the afﬂicted patients. Investigations conducted in the
early 1990s reported prevalence estimates of C–ISBs
ranging from 5% to 6% of the US population [80, 81]
(Table 1). Male patients have been traditionally re-
ported to be more afﬂicted than women by C–ISBs
[82, 83]. However, it is not clear how large this sex
difference is and the extent to which the difference is
due to men coming to the attention of professionals
with greater frequency. Studies assessing the rates of
OCD in patients suffering from C–ISBs [79, 84] re-
ported estimates around 12% and 14% (Table 2).
C–I shopping, also referred as compulsive buying,
is characterized by maladaptive preoccupations or
impulses to buy or shop that are experienced as
irresistible, intrusive and/or senseless, accompanied
by frequent episodes of buying items that are not
needed and/or that cost more than can be afforded.
Frequently, these patients engage in these behaviors
for longer periods of time than intended, and they
experience distress and signiﬁcant impairment in
social and occupational performance. As speciﬁed for
many other ICDs, the excessive buying or shopping
behavior does not occur exclusively during periods of
hypomania or mania [85, 86]. A recent study on C–I
shopping disorder estimated the prevalence of this
disorder to be between 2% and 8% of the general
adult population in the US [87]; 80% to 95% of those
affected are female (Table 1). Onset occurs in the late
teens or early twenties, and the disorder is generally
chronic. Previous studies investigating rates of OCD
in patients with C–I shopping reported rates of 12.5%
to 30% [86, 88] (Table 2); lower rates of compulsive
buying have been found in patients with OCD (from
2.2% to 10.6%) [59–61], except for the study of Le-
joyeux and colleagues (23.3%) [89].
Patients with C–I skin picking frequently present
to dermatologists, and it has been estimated that
about 2% of dermatology clinic patients may suffer
from this condition [90, 91] (Table 1). Prevalence in
the general population or in psychiatric clinics is
unknown. Skin picking is often not a transient
behavior but may persist with a waxing and waning
lifetime course. It should be considered pathological
when it becomes habitual, chronic and extensive,
leading to signiﬁcant distress, dysfunction or disﬁg-
urement [38]. As reported by two recent studies, the
majority of patients with C–I skin picking are women
and their condition is assumed to be chronic, with
excoriations on both single or multiple sites [92, 93];
the face is the most common site of excoriation but
picking can involve any area of the body. Both studies
found the majority of patients experienced increasing
tension before the act (79–81%), relief after the act
(52–79%), or both (68–90%). Comorbid lifetime rates
of skin picking in patients with trichotillomania were
approximately 10% in both studies [92, 93], whereas
comorbid lifetime OCD was present in rates ranging
from 6% to 19%. Wilhelm and colleagues [94] re-
ported rates of OCD around 52% in a sample of 31
patients with C–I skin picking (Table 2). As men-
tioned for trichotillomania, the inclusion of C–I skin
picking within a spectrum of self-injurious behaviors
is receiving increasing support from clinical and
neuroimaging studies [38].
Treatment options for ICDs
Treatment options for ICDs include both pharmaco-
therapy and psychotherapy. During the last decade,
increasing research has been conducted on different
pharmacological treatments across several ICDs;
however, while the efﬁcacy of various treatments has
been investigated in double-blind studies for certain
disorders (i.e., PG, IED, C–I shopping), systematic
research of clinical treatment is still lacking for other
disorders (see Table 3). In addition, a crucial issue to
take into account when considering pharmacotherapy
for patients with ICDs is the comorbidity with other
psychiatric conditions such as affective and addictive
disorders. The presence of bipolar or addictive com-
orbidity, in fact, will determine the most appropriate
choice when different treatments have proven to be
effective for a speciﬁc disorder.
PG is a good example of the importance of com-
orbidity determining treatment. PG has demonstrated
a good response to selective serotonin reuptake
inhibitors (SSRIs), mood stabilizers and opioid
antagonists in double-blind studies [22, 95–99] (Ta-
ble 3). Among all the antidepressants assessed so far,
ﬂuvoxamine [100], paroxetine [97, 98], citalopram
[101], nefazodone [102], bupropion [103], (although
only ﬂuvoxamine and paroxetine in double-blind
studies), the most convincing evidence is for the
efﬁcacy of the SSRIs. However, a major issue for this
class of medication is the presence of bipolar spec-
trum comorbidity in some gamblers. This possibility
needs to be carefully evaluated and excluded before
treating pathological gamblers with antidepressants in
order to avoid the possible reemergence of manic
symptoms. The opioid antagonist naltrexone was
effective in a double-blind trial, however, the risk of
hepatotoxicity of this drug limits its use. Of note, the
468opioid antagonist nalmefene has shown to be efﬁca-
cious in preliminary ﬁndings with better tolerability
than naltrexone [104]. Patients with other addictive
disorders (alcohol and other substances) and intense
urges and craving might particularly beneﬁt from
opioid antagonists. Mood stabilizers and anticonvul-
sants (lithium and divalproex assessed in double-
blind controlled trials) have shown good results in
recent studies without any speciﬁc contraindications
for their use across the different subtypes of gamblers.
In addition, gamblers with consistent affective insta-
bility may particularly beneﬁt from these treatments.
Pharmacological treatment of TTM is not well
established and, although SSRIs seem to show the best
efﬁcacy and safety, double-blind controlled studies on
their use have given mixed results (Table 3). Clo-
mipramine was found to be more effective than
desipramine in a 10-week crossover study [105]
conducted in the late 1980s. While subsequent
uncontrolled studies found ﬂuoxetine, ﬂuvoxamine
and citalopram to be efﬁcacious in patients with hair
pulling [106–110], two controlled studies [111, 112]
with ﬂuoxetine could not replicate the positive ﬁnd-
ings reported with SSRIs in the open-label trials. Po-
sitive results have been also reported in uncontrolled
studies with venlafaxine, lithium and naltrexone
[113–116] as well as in open-label augmentation
studies with SSRIs and pimozide [117, 118]. However,
treatment response is often disrupted by signiﬁcant
relapse during ongoing pharmacological treatment
[117]. In a recent controlled study [119] comparing
cognitive behavioral therapy (CBT) to clomipramine
and placebo, CBT had a dramatic effect in reducing
symptoms of TTM and was signiﬁcantly more effec-
tive than clomipramine or placebo, underscoring the
efﬁcacy of behavioral as well as pharmacological
treatment in hair pulling.
To our knowledge, no controlled pharmacological
trial has been conducted in patients with pyromania.
Non-pharmacological interventions for ﬁresetters,
Table 3 Treatment options for impulse control disorders as reported in blinded and unblinded studies
Impulse Control
Disorder
Double-blind studies
(references)
Outcomes Other treatment options as
reported in open-label trials
Pathological Gambling Fluvoxamine vs. PC (Hollander et al. 2000;
Blanco et al. 2002)
SSD for Fluvoxamine; No SSD
between Fluvoxamine and PC.
Nefazodone, Bupropion, Citalopram,
Divalproex, Topiramate
Paroxetine vs. PC (Kim et al. 2002;
Potenza et al. 2003)
SSD for Paroxetine; No SSD between
Paroxetine and PC.
Lithium vs. PC (Hollander et al. 2005) SSD for Lithium;
Naltrexone vs. PC (Kim et al. 2001) SSD for Naltrexone
Trichotillomania Clomipramine vs. Desipramine
(Swedo et al. 1989)
SSD for Clomipramine; Fluvoxamine, Citalopram, Venlafaxine,
Naltrexone, Lithium, CBT
Fluoxetine vs. PC (Christenson et al. 1991;
Streichenvein and Thornby 1995)
No SSD between Fluoxetine and PC
Pyromania – – CBT and other psychotherapies
Intermittent
Explosive Disorder
*Lithium vs. PC (Campbell et al. 1984 and
1995; Malone et al. 1998 and 2000)
SSD for Lithium (in the Campbell’
study of 1984, Lithium was
associated to Haloperidol)
Clonidine
*Divalproex vs. PC
(Hollander et al. 2003 and 2005)
SSD for Divalproex
*Fluoxetine vs. PC (Coccaro et al. 1997) SSD for Fluoxetine
*Carbamazepine vs. PC (Foster et al. 1989) SSD for Carbamazepine
*Phenytoin vs. PC (Barratt et al. 1997;
Stanford et al. 2001)
SSD for Phenytoin
*BBlockers vs. PC
(Greendyke et al. 1986a and 1986b)
SSD for BBlockers
*Risperidone vs. PC (Buitelaar et al. 2001;
Findling et al. 2001)
SS for Risperidone
*CBT vs. PC (Alpert et al. 1997) SSD for CBT
Kleptomania – – Fluoxetine, Paroxetine, Fluvoxamine,
Divalproex, Lithium, Benzodiazepines
C–I Internet Usage
Disorder
Escitalopram vs. PC
(Dell’Osso et al. 2006**)
SSD for Escitalopram Psychotherapy
C–I Shopping Fluvoxamine vs. PC (Black et al. 2000;
Ninan et al. 2000)
No SSD between Fluvoxamine
and PC;
Fluvoxamine, Naltrexone
Citalopram vs. PC (Koran et al. 2003) SSD for Citalopram
C–I Skin Picking Fluoxetine vs. PC (Simeon et al. 1997;
Block et al. 2000)
SSD for Fluoxetine Clomipramine, Sertraline
C–I Sexual Behaviors – – Lithium, Tricyclics, Buspirone,
Fluoxetine, Nefazodone,
Sertraline, Naltrexone
SSD = statistically significant differences; CBT = cognitive behavioral therapy; PC = placebo
* Studies on patients with impulsive aggression features, rather than with a proper DSM diagnosis of IED
** Open-label study followed by double-blind discontinuation phase (Abstract)
469including CBT [120], short-term counseling and day-
treatment programs [121], have shown some efﬁcacy.
Undoubtedly, pyromania represents an ICD needing
systematic pharmacotherapy research.
Treatment options for IED include the use of mood
stabilizers, phenytoin, SSRIs, b-blockers, a2-agonists
and antipsychotics (Table 3). Actually the majority of
trials with these compounds have been conducted on
individuals with impulsive aggression rather than
with a speciﬁc diagnosis of IED, and several authors
still don’t consider the current criteria for the diag-
nosis of IED to be adequate [122]. Nevertheless, the
presence of impulsive aggression within the core
features of IED allows us to put aside this nosographic
debate. Among mood stabilizers, the most convincing
evidence comes from controlled studies with lithium
(especially in children and adolescents) [123–127] and
divalproex [128]. This last medication demonstrated
signiﬁcant efﬁcacy in different populations of
aggressive subjects [129, 130]. Carbamazepine has
also shown some efﬁcacy in a small double-blind
study and in open-label trials [131, 132]. Phenytoin
has showed positive results in two controlled double-
blind studies [133, 134] at doses up to 300 mg/d. With
regard to SSRIs, a double-blind placebo controlled
trial of ﬂuoxetine [135] in patients with personality
disorder showed reduced scores on measures of irri-
tability and aggression in patients taking the active
medication. B-blockers propranolol and pindolol
have also shown positive results in controlled studies
[136, 137], reducing aggressive behaviors in patients
with brain damage, although their concomitant
diagnosis of IED might be arguable as the aggressive
behaviors may have a different etiology. The a-agonist
clonidine was reported to decrease aggression in an
open-label trial [138] with adolescents at dosages of
0.4 mg/d, although the tolerability was a problem for
some subjects. The atypical antipsychotic risperidone
was also showed to be effective in treating aggression
in controlled studies [139, 140]. Finally, controlled
studies of behavioral interventions including CBT,
group therapy, family therapy and social skill training
have shown them to be valid treatments for aggressive
patients [141, 142].
The pharmacological treatment of kleptomania in-
cludes SSRIs, mood stabilizers and opioid antagonists,
although none of these medications have been tested
in blinded, controlled trials so far (Table 3). Among
SSRIs, ﬂuoxetine, alone or in combination with lith-
ium or tricyclics, was shown to be effective in several
case-reports [64, 143, 144], as were ﬂuvoxamine and
paroxetine [145–148]. Mood stabilizer trials and re-
ports in kleptomanic patients showed mixed results
for lithium [64, 144, 145], valproic acid [64, 149] and
carbamazepine [64]. The opioid antagonist naltrexone
was reported to be effective in two different case re-
ports [148, 150]. Finally the benzodiazepines clo-
nazepam and alprazolam provided some evidence of
efﬁcacy in treating kleptomania [64, 147]. In conclu-
sion, as discussed in a recent review [151], SSRIs seem
to be the most promising treatment for kleptomania
(19 of 30 cases of successful pharmacotherapy re-
ported in the literature), either as monotherapy or in
combination with other psychotropic drugs.
Given its recent recognition as a psychiatric prob-
lem, understandably no controlled pharmacological
trials have been published on the treatment of C–I
Internet usage disorder so far. Recently, Sattar and
Ramaswamy [152] reported the case of a 31-year-old
man with severe Internet addiction successfully trea-
ted with escitalopram (10 mg/d). Most treatment
strategies for problematic Internet use have involved
behavioraltherapy techniques,whichlimit the amount
of time on the Internet rather than requiring absti-
nence, as is done with many other addictions such as
substance abuse. Self-help groups (both on and off-
line) are also being formed to address the problem.
Our group has recently completed an open-label trial
of escitalopram followed by a double-blind discon-
tinuation phase in a population of C–I Internet users
with preliminary positive ﬁndings [153]. Given the
increasing use of the Internet in the new generations, a
growing prevalence and incidence of this disorder is
arguable. Clinicians treating subjects with ICDs should
always assess the presence of this disorder in these
patients given the relationship between C–I Internet
use and some speciﬁc ICDs, such as pathological
gambling and C–I sexual behaviors [154, 155]. Finally,
controlled studies are expected in order to investigate
the treatment response of Internet addicted patients to
pharmacotherapy and psychotherapy.
Although C–I sexual behaviors seem relatively
common, controlled trials on pharmacological treat-
ments for these disorders are still lacking, and the
available literature on this topic consists essentially of
open-label trials and case-report series (Table 3). Po-
sitive ﬁndings have been reported with lithium and
tricyclics [156–158], SRIs [159–162], buspirone [163,
164] and nefazodone [165]. As for other ICDs, the
opioid antagonist naltrexone has recently shown to be
efﬁcaciousinsomecase-reports[166].Finally,different
formsofpsychotherapyhavebeenshowntobeeffective
for speciﬁc subtypes of C–I sexual behaviors [167].
There is some evidence that C–I shopping has been
effectively treated with several different compounds
(Table 3). McElroy’s group [86] reported on 20 pa-
tients that beneﬁted from antidepressants, often in
combination with mood stabilizers. Black [168] re-
ported ﬂuvoxamine to be effective in patients without
comorbid major depression, suggesting that
improvement was independent of the treatment of
mood symptoms. Naltrexone was found to be effective
in a case series [169]. Two double-blind placebo-
controlled trials [170, 171] did not conﬁrm the
superiority of ﬂuvoxamine over placebo. However,
these studies had the patients in both conditions keep
a log of their shopping; keeping logs is a therapeutic
intervention in itself and may have led to the failure of
470the ﬂuvoxamine and placebo groups to separate. An
open-label trial of citalopram [172] and a subsequent
open-label trial followed by double-blind discontin-
uation [173], neither of which using shopping logs,
reported positive results. Studies comparing the efﬁ-
cacy of pharmacological treatment with psychother-
apy have not been published yet.
Patients suffering from C–I skin picking often meet
criteria for other psychiatric disorders (BDD and
OCD), and frequently, due to medical complications
of their psychopathology such as infection and scar-
ring, they are referred to clinicians other than psy-
chiatrists (i.e. dermatologists). The ﬁrst controlled
trial conducted by our group [97] found ﬂuoxetine, at
a mean dose of 55 mg/d for 10 weeks, signiﬁcantly
superior to placebo in decreasing the behavior in 21
adults with chronic pathologic skin picking (Table 3).
More recently, a combined open-label and double-
blind trial [174] conﬁrmed the efﬁcacy of ﬂuoxetine in
subjects with C–I skin picking. Previously, a retro-
spective treatment review of BDD patients with skin
picking indicated that SRIs were effective in about
half of 33 patients, whereas other agents were not
[175]. In a subsequent open-label study [176], sertr-
aline (mean dose: 95 mg/d) showed clinically signiﬁ-
cant improvement in 68% of 30 patients with skin
picking after one month of treatment. Finally,
uncontrolled psychodynamically oriented treatments
and behavioral interventions have given mixed results
described elsewhere [177].
Conclusions
Current knowledge on ICDs in terms of epidemiology
and pharmacological treatment varies notably across
these disorders, with recent and continuing advances
for some (i.e. pathological gambling and C–I shop-
ping), and anecdotal and obsolete data for others.
Undoubtedly, given the high prevalence estimates of
some ICDs (i.e. pathological gambling and C–I sexual
behaviors) as well as their comorbidity with other
major psychiatric disorders, this group of disorders
represents a global problem. Nevertheless, certain
ICDs (i.e, pyromania, C–I Internet usage disorder)
still need systematic epidemiological and pharmaco-
logical research.
Studying the relationships between speciﬁc ICDs
and other major psychiatric conditions (i.e. OCD,
bipolar disorders, addictive disorders) in terms of
phenomenological issues and comorbidity patterns is
not only of theoretical interest; indeed, it provides the
rationale for the use of speciﬁc pharmacological
treatments and behavioral interventions. From this
perspective, more than one decade after its intro-
duction, the conceptualization of ICDs as obsessive–
compulsive related disorders is still valid and has
been conﬁrmed by numerous studies; however, there
is also evidence supporting the relationship between
ICDs and addictive and affective disorders. Not only
are the different models of conceptualizing the ICDs
not mutually exclusive, but they can contribute to
recognize speciﬁc subtypes within the disorders. As a
result, different models of conceptualization of ICDs
have led new developments in pharmacologic treat-
ment of these disorders, with positive results obtained
with mood stabilizers and opioid antagonists in
addition to the SSRIs.
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